# Ainos, Inc.: Form 10-Q for the period ended Sep 30, 2018

- Company: [Ainos, Inc.](/companies/aimd.md) (CIK 1014763)
- Form: 10-Q
- Filed: 2018-11-14
- Accepted by EDGAR: Nov 14, 2018, 14:40 ET
- Period: 2018-09-30
- Accession: 0001014763-18-000019
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1014763/000101476318000019/form10-q_09302018.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1014763/000101476318000019/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2018-07-01 to 2018-09-30 | $14.9k | us-gaap:Revenues |
| Revenue | 9 months, 2018-01-01 to 2018-09-30 | $71.7k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2018-07-01 to 2018-09-30 | $16.8k | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2018-01-01 to 2018-09-30 | $60.8k | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2018-07-01 to 2018-09-30 | −$1.9k | us-gaap:GrossProfit |
| Gross profit | 9 months, 2018-01-01 to 2018-09-30 | $10.9k | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2018-07-01 to 2018-09-30 | $307.0k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2018-01-01 to 2018-09-30 | $860.0k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2018-07-01 to 2018-09-30 | −$308.8k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2018-01-01 to 2018-09-30 | −$849.0k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2018-07-01 to 2018-09-30 | $1.2k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2018-01-01 to 2018-09-30 | $3.5k | us-gaap:InterestExpense |
| Diluted EPS | 3 months, 2018-07-01 to 2018-09-30 | −$0.01 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2018-01-01 to 2018-09-30 | −$0.02 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2018-01-01 to 2018-09-30 | −$697.3k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2018-01-01 to 2018-09-30 | $4.9k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2018-09-30 | $1.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2018-09-30 | $1.2m | us-gaap:AssetsCurrent |
| Total assets | at 2018-09-30 | $1.5m | us-gaap:Assets |
| Current liabilities | at 2018-09-30 | $707.3k | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2018-09-30 | $707.3k | us-gaap:Liabilities |

## Management's discussion and analysis

As filed, 14,369 characters.

*The following discussion should be read in conjunction with our financial statements and the notes thereto which appear elsewhere in this report. The results shown herein are not necessarily indicative of the results to be expected in any future periods.*

Forward-Looking Statements: Certain statements made throughout this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance, achievements, costs or expenses and may contain words such as "believe," "anticipate," "expect," "estimate," "project," "budget," or words or phrases of similar meaning. Forward-looking statements involve risks and uncertainties which may cause actual results to differ materially from those projected in the forward-looking statements. Such risks and uncertainties are detailed from time to time in reports filed by the Company with the Securities and Exchange Commission, including Forms 8-K, 10-Q and 10-K and include among others the following: promulgation and implementation of regulations by the U.S. Food and Drug Administration ("FDA"); promulgation and implementation of regulations by foreign governmental instrumentalities with functions similar to those of the FDA; costs of research and development and trials, including without limitation, costs of clinical supplies, packaging and inserts, patient recruitment, trial monitoring, trial evaluation and publication; and possible difficulties in enrolling a sufficient number of qualified patients for certain clinical trials. The Company is also dependent upon a broad range of general economic and financial risks, such as possible increases in the costs of employing and/or retaining qualified personnel and consultants and possible inflation which might affect the Company's ability to remain within its budget forecasts. The principal uncertainties to which the Company is presently subject are its inability to ensure that the results of trials performed by the Company will be sufficiently favorable to ensure eventual regulatory approval for commercial sales, its inability to accurately budget at this time the possible costs associated with hiring and retaining of additional personnel, uncertainties regarding the terms and timing of one or more commercial partner agreements and its ability to continue as a going concern.

The risks cited here are not exhaustive. Other sections of this report may include additional factors which could adversely impact the Company's business and future operations. Moreover, the Company is engaged in a very competitive and rapidly changing industry.

New risk factors emerge from time to time and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such risk factors on the Company's business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those projected in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual future events.

**Overview.** ABI is engaged in the business of biopharmaceutical research and development. Its primary focus historically has been the development of low-dose, orally administered interferon. ABI holds or licenses various patents; it also is the developer of Maxisal®, a dietary supplement to treat dry-mouth symptoms.

The Company's goal continues to be the expansion of the reach of its research, development, and marketing of biopharmaceutical, biotechnical, health and life science related products. ABI will continue to leverage its core technology going forward by using its scientific and clinical data to establish interferon-alpha lozenges as a therapeutic agent for conditions such as influenza, hepatitis C, and various causes of thrombocytopenia just to name a few. The Company is committed to expanding its business operations from the currently narrow focus to encompass a wide variety of licensing, partnerships, joint ventures and other development opportunities in the aforementioned sectors. This commitment extends not only to the U.S., but to Taiwan, China, and other Asian Countries.

ABI holds various patents and related intellectual property. The most significant asset is intellectual property consisting of six patents, five in the U.S. and one in Taiwan. Additionally, we have one trademark. One of the patents expires in April 2019, and another patent will expire in April 2021. The newest patents will expire in April and May 2033. These patents will not have significant value unless commercialized, which will require adequate funding, time, effort, and expertise in biologics. ABI is intensifying its exploration of new and more cost efficient interferon sources with which to advance its core technology. The anticipated location and development time required for a new source of human interferon along with the requisite testing and FDA approval time could exceed the life span of all but the newest of the patents, and even if it does not, could leave relatively little time to derive revenues from the patent protections, prior to patent expiration. The patent which carries the trademark, a product promoting oral health, also is the subject of supply-chain interruption because the supplier of the raw material for the product (anhydrous crystalline maltose, or ***"ACM"***) has substantially increased its purchase price and minimum purchase quantity. Additionally, there is currently no competitive, satisfactory alternative material. The price increase and other actions have rendered the manufacture and sale of the product less attractive.

It is anticipated that ABI will attempt to monetize and commercialize its existing intellectual property, which would necessitate identification and acquisition of new source product (e.g., Interferon), conducting new trials, and additional protection of intellectual property. It is estimated this may require additional funding (including general administrative cost and professional fees) of between $500,000 and $800,000. ABI has acquired new product lines and continues to explore the acquisition and development of additional new product lines. The cost to commercialize any such development could likely require a similar funding level, resulting in aggregate funding requirements between $1 million and $1.6 million. These activities, even if undertaken, would not be expected to produce revenue before the last calendar quarter of 2019, or possibly later.

New technologies are anticipated to be developed and introduced to market. This includes proprietary technology, protocol knowledge bases, and clinical patient data to treat metabolic diseases such as Type 1 and 2 diabetes and numerous other metabolism related disorders.

### Results of Operations for Quarters Ended September 30, 2018 and 2017:

**Revenues.** There were minimal revenues for the quarter ended September 30, 2018, $14,908 as compared to September 30, 2017, which had no revenue to recognize.

**Cost of Revenues.** For the quarter ended September 30, 2018, the cost of the revenues was $16,791. For the same quarter in 2017, there were no costs of revenues.

**Research and Development Expenses.** There was no direct R&D activity for the quarters ended September 30, 2018 or September 30, 2017.

**Selling, General and Administrative Expenses.** Selling, general and administrative expenses of $306,965 were incurred for the third quarter in 2018, as compared to $230,875 for the third quarter of 2017, an increase of $76,090 (33%). Salary and stock compensation expenses were $137,665 in 2018 from $89,157 in 2017, a $48,508 increase (54%).

These increases were due to growing foreign operations. Professional fees for accounting increased $5,026 (98%) to $10,138 in 2018 from $5,112 in 2017. Professional consulting fees increased to $43,677 in 2018 from $27,699 in 2017, an increase of $15,978 (58%). The increased accounting and consulting fees were incurred due to the expansion of foreign operations.

**Operating Income (Loss).** In the three-month period ended September 30, 2018, the Company's operating loss of $308,848 compared to operating loss of $230,875 for the three-month period ended September 30, 2017, a $77,973 increase in loss. There were more expenses overall during the third quarter of 2018 due to increased foreign operations.

**Interest Expense.** During the three-month period ended September 30, 2018, interest expense was $1,191, compared to $1,929 for the three-month period ended September 30, 2017. The reduced interest expense in the third quarter of 2018 is mostly due to debt reduction of Dr. Stephen Chen's unsecured loans by repayments of the debt by ABI as well as Dr. Chen's conversion of debt to equity.

**Net Income (Loss).** In the three-month period ended September 30, 2018, the Company had net loss of $310,039 compared to a net loss of $232,804 for the three-month period ended September 30, 2017, a $77,235 increase in loss. This increase was mainly due to increased selling, general and administrative expenses.

### Results of Operations for the Nine Months Ended September 30, 2018 and 2017:

**Revenues.** Revenue now includes that which was generated by the Taiwan Branch Office. A portion of the revenue for the nine months, $1,960, was generated by the marketing of a new wound-closure product, TissueAid®. The total revenue recognized through September 30, 2018, was $71,748 against $250,502 from the sale of metabolism treatment equipment, in 2017, a decrease in 2018 of $178,754 (71%). This decrease of revenue is mostly due to no sales of metabolism treatment equipment in 2018.

**Cost of Revenues.** Cost of sales for the nine months ended September 30, 2018 was $60,837. For the nine months ended September 30, 2017, there was $58,801 of nutraceutical products purchased, an increase of $2,036 for 2018 (3%). In 2017 we purchased metabolism treatment equipment in the amount of $58,801, compared to no equipment purchases in 2018.

**Research and Development Expenses.** There was no direct R&D activity for the nine months ended September 30, 2018, or September 30, 2017.

**Selling, General and Administrative Expenses.** Selling, general and administrative expenses of $859,956 were incurred for the first nine months of 2018, compared to $592,822 for the first nine months of 2017, an increase of $267,134 (45%). This increase is mostly due to additional salary expense in 2018, $325,081, over $180,874 in 2017, an increase of 80% ($144,207); and stock compensation expense of $84,000 in 2018 over $63,750 in 2017, an increase of $20,250 (32%). Travel expense has increased $28,673 (160%) in 2018, to $46,595 from $17,922 in 2017. Accounting fees rose 63%, to $42,861 in 2018, from $26,347, over the same period in 2017, an increase of $16,514. In 2018 for the first nine months, rent increased by $20,107 (81%) to $44,847 in 2018 from $24,740 in 2017.

Professional consulting fees increased to $99,585 in 2018 from $52,634 in 2017, an increase of $46,951 (89%). The increases in these expenses were due to the growth and expansion of foreign operations.

**Operating Loss.** In the nine months ended September 30, 2018, the Company's operating loss was $849,045 compared to an operating loss for the nine month period ended September 30, 2017 of $401,121, a $447,924 (112%) increase. The increased selling, general, and administrative expense increases along with no significant sales in 2018 was a major factor in the operating loss increase. However, a major portion of the expense increases were driven by expanded international operations and activities.

**Interest Expense.** During the nine-month period ended September 30, 2018, interest expense was $3,544, compared to $7,630 for the nine-month period ended September 30, 2017. The reduced interest expense for the nine-month 2018 period, $4,086 (54%), is mostly due to debt reduction of Dr. Stephen Chen's unsecured loans by ABI's repayments of the debt as well as Dr. Chen's conversion of debt to equity.

**Net Loss.** The Net Loss for the first nine months of 2018, increased to $852,589 from $408,751 in 2017, an increase of $443,838, (109%) for the period. The increase in net loss is due to the decrease in revenue in the three quarters of 2018 and the increase in expenses due to incorporation of operations of the Taiwan office.

**Liquidity Needs.** At September 30, 2018, we had available cash of $1,143,317 whereas we had a cash position of $1,980,015 as of December 31, 2017. The Company had a working capital of $488,876 as of September 30, 2018. For 2017, the working capital was $261,412. Historically the net cash loss has been between $50,000 and $60,000 per month. It is difficult to estimate the burn rate at this point insomuch as foreign operations have increased and new budgets are being developed for escalations in R&D spending and foreign operations. One of the Company's main goals is to return to the status of a going concern by having reduced operating losses and subsequently becoming profitable. As indicated throughout this document, two other major goals of ABI are to (1) leverage the core technology, low-dose oral interferon, and (2) diversify Company operations to incorporate additional lines of business which will extend the reach of ABI into additional economic sectors such as biotech / bio-pharmaceutical / health care products and life sciences business. ABI estimates its financing needs to be between $1,000,000 and $1,600,000 to support our core technology, which is included in the Pharmaceutical Division, and instituting new revenue streams with the Medical Division and the Consumer Products Division. The Company has also instituted a new corporate division, the Business Development Division dedicated to finding and developing new customers, markets, distribution channels, strategic partners, joint ventures, and other growth and expansion vehicles and opportunities.

There can be no assurance that we will be successful in our efforts to make the Company profitable. If those efforts are not successful, we could be forced to cease operations.

## Controls and procedures

As filed, 4,536 characters.

### Disclosure Controls and Procedures

At the end of the period covered by the Annual Report on Form 10-K for the fiscal year ended December 31, 2017, and this Form 10-Q Quarterly Report for the quarter ending September 30, 2018, an evaluation was carried out under the supervision of and with the participation of our management, including the Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), of the effectiveness of the design and operations of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act). Based on that evaluation, the CEO and the CFO have concluded that as of the end of the period covered by the Annual Report and Quarterly Report, our disclosure controls and procedures were not effective in ensuring that: (i) information required to be disclosed by us in reports that we file or submit to the SEC under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in applicable rules and forms and (ii) material information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow for accurate and timely decisions regarding required disclosure.

### Changes to Internal Controls and Procedures over Financial Reporting

There were no changes in our internal controls over financial reporting that occurred during the quarterly period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

### Management's Remediation Plans

Our management is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles ("GAAP"). Management has assessed the effectiveness of internal control over financial reporting based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO") in *Internal Control-Integrated Framework*. A material weakness, as defined by SEC rules, is a control deficiency, or combination of control deficiencies, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses in internal control over financial reporting that were identified are:

a) We did not maintain sufficient personnel with an appropriate level of technical accounting knowledge, experience, and training in the application of GAAP commensurate with our complexity and our financial accounting and reporting requirements. We have limited experience in the areas of financial reporting and disclosure controls and procedures. Also, we do not have an independent audit committee. As a result, there is a lack of monitoring of the financial reporting process and there is a reasonable possibility that material misstatements of the financial statements, including disclosures, will not be prevented or detected on a timely basis; and b) Due to our small size, we do not have a proper segregation of duties in certain areas of our financial reporting process. The areas where we have a lack of segregation of duties include cash receipts and disbursements, approval of purchases and approval of accounts payable invoices for payment. This control deficiency, which is pervasive in nature, results in a reasonable possibility that material misstatements of the financial statements will not be prevented or detected on a timely basis.

c) We do not have sufficient controls over authorization and documentation of revenue and equity transactions.

We will look to increase our personnel resources and technical accounting expertise within the accounting function as funds become available. Management believes that hiring additional knowledgeable personnel with technical accounting expertise will remedy the following material weakness: insufficient personnel with an appropriate level of technical accounting knowledge, experience, and training in the application of GAAP commensurate with our complexity and our financial accounting and reporting requirements. Additionally, we have engaged an Executive Advisor and an Accounting & Reporting Advisor to consult with the Company on various areas.

Filed Nov 14, 2018.
Source: SEC EDGAR, the filing index for accession 0001014763-18-000019. Last ingested by Listed: Nov 11, 2026, 00:28 ET. No prices; not investment advice.
